{"id":"NCT00563368","sponsor":"VIVUS LLC","briefTitle":"A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults","officialTitle":"A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2007-11-26","resultsPosted":"2012-09-03","lastUpdate":"2015-03-30"},"enrollment":756,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"VI-0521","otherNames":[]},{"type":"DRUG","name":"VI-0521","otherNames":[]},{"type":"DRUG","name":"topiramate","otherNames":[]},{"type":"DRUG","name":"topiramate","otherNames":[]},{"type":"DRUG","name":"phentermine","otherNames":[]},{"type":"DRUG","name":"phentermine","otherNames":[]},{"type":"DRUG","name":"VI-0521","otherNames":[]}],"arms":[{"label":"VI-0521 Top","type":"EXPERIMENTAL"},{"label":"VI-0521 Mid","type":"EXPERIMENTAL"},{"label":"TPM 46","type":"ACTIVE_COMPARATOR"},{"label":"TPM 92","type":"ACTIVE_COMPARATOR"},{"label":"PHEN 7.5","type":"ACTIVE_COMPARATOR"},{"label":"PHEN 15","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.","primaryOutcome":{"measure":"Percent Weight Loss From Baseline to Week 28","timeFrame":"baseline to 28 weeks","effectByArm":[{"arm":"Placebo","deltaMin":1.7,"sd":0.61},{"arm":"PHEN 7.5 mg","deltaMin":5.5,"sd":0.61},{"arm":"TPM 46 mg","deltaMin":5.1,"sd":0.61},{"arm":"VI-0521 Mid","deltaMin":8.5,"sd":0.62},{"arm":"PHEN 15 mg","deltaMin":6.1,"sd":0.61},{"arm":"TPM 92 mg","deltaMin":6.4,"sd":0.62},{"arm":"VI-0521 Top","deltaMin":9.2,"sd":0.61}],"pValues":[{"comp":"OG005 vs OG006","p":"0.0009"},{"comp":"OG004 vs OG006","p":"0.0001"},{"comp":"OG000 vs OG006","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"0.0003"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["Headache","Paresthesia","Upper Respiratory Tract Infection","Dry Mouth","Nasopharyngitis"]}}